EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stenotrophomonas maltophilia bacteremia in adult patients with hematological diseases: clinical characteristics and risk factors for 28-day mortality

Wenjing Guo, Qingsong Lin, Jia Li, Xiaomeng Feng, Sisi Zhen, Yingchang Mi, Yizhou Zheng, Fengkui Zhang, Zhijian Xiao, Erlie Jiang, Mingzhe Han, Jianxiang Wang und 1 weitere

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.01011-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Wenjing Guo und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Stenotrophomonas maltophilia, Gram-Negative Bacterial Infections, Anti-Bacterial Agents, Hematologic Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, Tianjin Municipal Science and Technology Committee (Tianjin Municipal Science and Technology Commission).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with hematological diseases are at high risk for Stenotrophomonas maltophilia (SM) bacteremia. This study retrospectively analyzed the clinical characteristics and risk factors for 28-day mortality among 140 adult hematological patients diagnosed with SM bacteremia from January 2012 to July 2023. he overall 28-day mortality was 31.43% (44/140), with a median age of 44 years. The median hospital stay before SM bacteremia onset was 25 days, and 69.29% of patients had unresolved neutropenia. All patients had received broad-spectrum antibiotics in the past month, and 69.29% developed breakthrough bacteremia during carbapenem therapy. Independent risk factors for mortality included a Sequential Organ Failure Assessment (SOFA) score ≥5, tigecycline exposure, age ≥60, and pulmonary infection. Patients with ≥2 risk factors were stratified into the high-risk group, with a significantly higher 28-day mortality compared with the low-risk group (56.52% vs 7.04%, P < 0.001). Treatment with trimethoprim-sulfamethoxazole (TMP/SMX) ( P = 0.008) or TMP/SMX combined with cefoperazone/sulbactam (CSL) ( P = 0.005) was associated with survival benefits among high-risk patients. Overall, SM bacteremia usually occurs in hematological patients with prolonged hospitalization, unresolved neutropenia, and extensive use of broad-spectrum antibiotics, especially carbapenems. Patients with high SOFA scores, advanced age, pulmonary infection, or recent tigecycline exposure are at higher risk of mortality. The preferred treatment is TMP/SMX rather than fluoroquinolones, with combination therapy of TMP/SMX and CSL considered a feasible treatment option. IMPORTANCE This study, representing the largest cohort of adult hematological patients with SM bacteremia to date, strengthens the validity of existing findings and provides new insights into its clinical management. We identify risk factors for 28-day mortality, revealing that patients with two or more risk factors experience particularly high mortality rates. This highlights the importance of early identification and targeted management of high-risk individuals. Our findings also demonstrate that TMP/SMX is superior to fluoroquinolones and suggest that combining TMP/SMX with CSL may offer additional survival benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stenotrophomonas maltophiliaGram-Negative Bacterial InfectionsAnti-Bacterial AgentsHematologic DiseasesHumansMaleAdultMiddle AgedFemaleRisk FactorsRetrospective StudiesAgedTigecyclineYoung AdultTrimethoprim, Sulfamethoxazole Drug CombinationBacteremia

Stichwörter der Autor:innen

Stenotrophomonas maltophiliabacteremiahematological diseaserisk factorstreatment

Substanzen

Anti-Bacterial AgentsTigecyclineTrimethoprim, Sulfamethoxazole Drug Combination

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
  • Tianjin Institutes of Health Science, Tianjin, China.

ORCID-Profile: Sizhou Feng

Förderung

  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
  • Tianjin Municipal Science and Technology Committee (Tianjin Municipal Science and Technology Commission)

Zitieren

APA

Guo, W., Lin, Q., Li, J., Feng, X., Zhen, S., Mi, Y., Zheng, Y., Zhang, F., Xiao, Z., Jiang, E., Han, M., Wang, J., & Feng, S. (2025). Stenotrophomonas maltophilia bacteremia in adult patients with hematological diseases: clinical characteristics and risk factors for 28-day mortality. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01011-24

Vancouver

Guo W, Lin Q, Li J, Feng X, Zhen S, Mi Y, et al. Stenotrophomonas maltophilia bacteremia in adult patients with hematological diseases: clinical characteristics and risk factors for 28-day mortality. Microbiology Spectrum. 2025. doi:10.1128/spectrum.01011-24

BibTeX
@article{Guo2025,
  author = {Guo, Wenjing and Lin, Qingsong and Li, Jia and Feng, Xiaomeng and Zhen, Sisi and Mi, Yingchang and Zheng, Yizhou and Zhang, Fengkui and Xiao, Zhijian and Jiang, Erlie and Han, Mingzhe and Wang, Jianxiang and Feng, Sizhou},
  title = {Stenotrophomonas maltophilia bacteremia in adult patients with hematological diseases: clinical characteristics and risk factors for 28-day mortality},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.01011-24}
}
Kostenlos starten →